OncoMatch/Clinical Trials/NCT06151262
A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer
Is NCT06151262 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trilaciclib+mFOLFIRINOX for pancreatic cancer.
Treatment: Trilaciclib+mFOLFIRINOX — To observe the incidence of chemotherapy-induced myelosuppression and the safety of Trilaciclib combined with mFOLFIRINOX in patients with advanced pancreatic cancer receiving first-line treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic antineoplastic therapy
Had received systemic antineoplastic therapy
Lab requirements
Blood counts
Neutrophil count ≥1.5×10^9/L; Hemoglobin ≥10g/dL; Platelet count ≥100×10^9/L
Kidney function
creatinine clearance(CCr)≥60ml/min
Liver function
Total bilirubin(TBIL)≤1.5×ULN; ALT and AST≤1.5×ULN
Major organ functions within 7 days prior to treatment shall meet the following criteria: a. Neutrophil count ≥1.5×10^9 /L； b. Hemoglobin ≥10g/dL； c. Platelet count ≥100×10^9 /L Biochemical examination shall meet the following standards: a、Total bilirubin(TBIL)≤1.5times the upper limit of normal value(ULN); b、ALT and AST≤1.5×ULN ; c、creatinine clearance(CCr)≥60ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify